GENE ONLINE|News &
Opinion
Blog

Aducanumab
EMA Rejects Marketing Authorization Application of Aduhelm
2021-12-20
AC Immune’s Stock Climbs Following Mixed Phase 2 Trial Results for Alzheimer’s Disease Drug
2021-09-01
Aftermath of Biogen’s Alzheimer’s Drug Approval Continues as Some Hospitals, Insurers Refuse Administration
2021-07-18
Biogen’s Controversial Alzheimer’s Drug Wins Historic FDA Approval
2021-06-07
Lilly’s Positive Data for Alzheimer’s Drug Bodes Well for Candidates Rooted in Amyloid Hypothesis
2021-03-14
Biogen’s Alzheimer’s Drug Turned Down by Independent Panel
2020-11-07
Biogen Stocks Rise Following FDA’s Inspiriting Comments on Alzheimer’s Drug, Aducanumab
2020-11-05
GeneOnline’s Top Ten Headlines of the Year
2019-12-30
LATEST
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
EVENT
Scroll to Top